Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6420852 | 0.78 | ELANE (0.48) | ELANEMAPK1FAAHNR1H2MAPT | |
| SCHEMBL16373419 | 0.74 | ELANE (0.52) | ELANEFAAHNR1H2MAPTESR2 | |
| SCHEMBL2208073 | 0.70 | ELANE (0.62) | ELANEFAAHGPR119 | |
| SCHEMBL27922069 | 0.70 | ELANE (0.49) | ELANEFAAHNR1H2GPR119MAPT | |
| SCHEMBL28361733 | 0.69 | ELANE (0.54) | ELANEFAAHNR1H2GPR119MAPT | |
| SCHEMBL29207748 | 0.69 | ELANE (0.47) | ELANEFAAHNR1H2GPR119MAPT | |
| SCHEMBL12510895 | 0.69 | ELANE (0.53) | ELANEGPR119MAPT | |
| SCHEMBL2208532 | 0.69 | ELANE (0.53) | ELANEFAAHGPR119 | |
| SCHEMBL2207579 | 0.68 | ELANE (0.52) | ELANEGPR119 | |
| SCHEMBL21241142 | 0.67 | ELANE (0.45) | ELANEFAAHNR1H2GPR119GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2676961-B1 | Combination drugs comprising aminotetrahydropyrans as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK SHARP & DOHME (US) | 2017-04-19 | — | — | EP | disclosed |
| EP-2676960-B1 | Combination drugs comprising aminotetrahydropyrans as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK SHARP & DOHME (US) | 2017-04-19 | — | — | EP | disclosed |
| US-9403790-B2 | Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20160137622-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME LLC | 2016-05-19 | — | — | US | disclosed |
| US-9278976-B2 | Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes | MERCK SHARP & DOHME CORP. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20150344487-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC | 2015-12-03 | — | — | US | disclosed |
| US-9138426-B2 | Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes | MERCK SHARP & DOHME CORP. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20150126443-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC | 2015-05-07 | — | — | US | disclosed |
| US-8951965-B2 | Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20140287993-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME LLC | 2014-09-25 | — | — | US | disclosed |
| EP-2676959-A1 | Combination drugs comprising aminotetrahydropyrans as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | Merck Sharp & Dohme Corporation (US) | 2013-12-25 | — | — | EP | disclosed |
| US-8592371-B2 | Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARPE & DOHME CORP. (US) | 2013-11-26 | — | — | US | disclosed |
| EP-2358717-B1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME (US) | 2013-08-21 | — | — | EP | disclosed |
| US-20130157940-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME CORP (US) | 2013-06-20 | — | — | US | disclosed |
| US-8415297-B2 | Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20120149637-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME LLC | 2012-06-14 | — | — | US | disclosed |
| US-8143289-B2 | Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2012-03-27 | — | — | US | disclosed |
| EP-2358717-A1 | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | Merck Sharp & Dohme Corp. (US) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010056708-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME CORP. (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20100120863-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME LLC | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120863-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | DPP4, DPP3, DPP7 | ELANE 908/4885MAPK1 3960/4885FAAH 1015/4885 |
| US-20150126443-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | DPP4, DPP3, DPP7 | ELANE 953/4885MAPK1 4151/4885FAAH 1006/4885 |
| US-20130157940-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | DPP4, DPP3, DPP7 | ELANE 908/4885MAPK1 3960/4885FAAH 1015/4885 |
| US-20150344487-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | DPP4, DPP3, DPP7 | ELANE 953/4885MAPK1 4151/4885FAAH 1006/4885 |
| US-20140287993-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | DPP4, DPP3, DPP7 | ELANE 908/4885MAPK1 3960/4885FAAH 1015/4885 |
| US-20120149637-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | DPP4, DPP3, DPP7 | ELANE 908/4885MAPK1 3960/4885FAAH 1015/4885 |
| US-20160137622-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | DPP4, DPP3, DPP7 | ELANE 908/4885MAPK1 3960/4885FAAH 1015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.